Both warfarin and direct oral anticoagulants are susceptible to drug-drug interactions (DDIs). DDIs are an important cause of adverse drug reactions and exact a large toll on the health care system.

Shares of BioNTech SE were soaring in early Monday trading, after Bristol Myers Squibb Co. made an $11.1 billion splash in the rapidly growing new cancer-drug game. The deal announced by Bristol ...

Drugs were a big part of Sean “Diddy” Combs’ life and so-called “freak-offs,” the jury in the Bad Boy Records founder’s sex-trafficking trial have repeatedly heard, and this morning ...

As President Trump touts his own executive orders to lower drug prices, the Medicare drug price negotiations begun during the Biden administration are continuing behind the scenes. Two companies ...

Regeneron Pharmaceuticals announced the interim results of its Phase 2 COURAGE trial Monday, which tested a combination of semaglutide (the active ingredient in popular drugs Ozempic and Wegovy ...

SAN ANTONIO — A shooting led to the discovery of drugs and weapons at a far west-side San Antonio home, where the Bexar County Sheriff's Office said a father and son were arrested. Sheriff ...

GLP-1 drugs like Ozempic and Wegovy might help you ditch the food baby, but they could also affect your ability to make a real one. Ayla Barmmer, a registered dietitian and reproductive health ...

Copyright 2025 The Associated Press. All Rights Reserved. Copyright 2025 The Associated Press. All Rights Reserved. British nationals, from left, Phineas Float ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy.

In December, the U.S. Food and Drug Administration (FDA) approved a new treatment for people with insomnia, Dayvigo (lemborexant). The drug will be available in 5 or 10 milligram (mg) doses ...

By tracing the temporal arc of medication UM, we aim to better understand its broader implications for future health care policy. We examine the evolution of UM over time, trends in its use ...

Between 1995 and 2021 private money spent on Alzheimer’s research came to $42.5bn, but more than 140 trials failed to yield a single drug capable of slowing the disease. Yet the tide may be turning.